

Table of Contents

About the Editor and Authors	v
Foreword	xlv
List of Terms and Abbreviations	xlix
CHAPTER 1	
Overview of European Pharmaceutical Regulatory Requirements <i>Sally Shorthose</i>	1
§1.01 Introduction	1
[A] History of Pharmaceutical Regulation	1
[B] The European Union	3
[C] Major EU Pharmaceutical Legislation	4
[D] Key EU Pharmaceutical Reform Legislation	5
[E] National Law and Interface with EU Directives	5
§1.02 Definitions	6
[A] Medicinal Product	6
[B] Generic Medicinal Products	6
[C] Paediatric Medicines	7
[D] Orphan Drugs	7
[E] Biotechnology-Derived Medicinal Products	8
[F] Homeopathic Medicinal Products	8
[G] Herbal Medicinal Products	9
[H] Traditional Herbal Medicinal Products	9
[I] Radiopharmaceuticals	10
[J] Non-prescription Medicines	10
[K] Immunological Medicinal Products	11
[L] Medical Devices	11
§1.03 The Regulatory Agencies	12
[A] The European Commission	12

Table of Contents

	[1] DG Health and Consumers (Commonly Known as 'SANCO')	13
	[a] The Public Health Unit	13
	[b] Biotechnology	14
	[2] The European Medicines Agency	14
[B]	Committees of the EMA	15
	[1] The Committee for Medicinal Products for Human Use	15
	[2] The Committee for Medicinal Products for Veterinary Use	16
	[3] The Committee for Orphan Medicinal Products	17
	[4] The Committee on Herbal Medicinal Products	18
	[5] The Paediatric Committee	18
	[6] Committee for Advanced Therapies	19
	[7] Pharmacovigilance Risk Assessment Committee	20
[C]	The Heads of Medicines Agencies	21
[D]	National Competent Authorities of European Member States	21
[E]	Coordination Group for Mutual Recognition and Decentralised Procedures: Human (CMD(h))	22
[F]	European Directorate for the Quality of Medicines	23
[G]	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use	23
§1.04	Applicable EU Legislation, Including Regulations and Guidance	24
	[A] EU Treaties	24
	[B] Directives	24
	[C] Regulations	25
	[D] The Official Journal of the European Communities	25
	[E] Guidelines	25
§1.05	Guidelines/Publications	27
CHAPTER 2		
Clinical Trials		
	<i>Sally Shorthose</i>	29
§2.01	Introduction	29
§2.02	Directive 2001/20/EC: The Clinical Trials Directive ('CTD')	31
	[A] Introduction to the CTD	31
	[B] When the CTD Applies	31
	[C] Implementation of the CTD	32
	[D] Aims of the CTD	33
	[E] Revision of the CTD/Introduction of a New Regulation	34
§2.03	Preparing to Commence a Clinical Trial	34
	[A] Introduction to the Commencement of a Clinical Trial	34
	[B] The Sponsor	35
	[1] Overall Sponsor Duties	35
	[2] Duty to Create the Trial Protocol	36
	[3] Duty to Select an Investigator and an Institution	37

Table of Contents

	[4] Duty to Create the Investigator's Brochure	37
	[5] Duty to Provide Quality Control	39
	[C] The Investigator	39
	[D] The Trial Identification Number	39
	[E] Advance Requests for EMA Advice	40
§2.04	Approval to Commence a Clinical Trial	41
	[A] Introduction to the Clinical Trial Approval Process	41
	[B] Ethical Committee Approval	42
	[1] Ethical Committee Approval Process	42
	[2] Informed Consent	43
	[3] The Ethical Committee Opinion	44
	[4] Ethical Committee Approval in Multi-State Trials	45
	[C] Trial Authorisation	46
§2.05	Conduct of the Clinical Trial	46
	[A] Introduction to the Conduct of Clinical Trials	46
	[B] GCP Standards	47
	[C] Good Manufacturing Practice	49
§2.06	Clinical Trial Oversight	50
	[A] Introduction to Clinical Trial Oversight	50
	[B] Monitoring	51
	[C] GCP Inspection	53
	[D] Internal Audit	54
	[E] Sponsor and Investigator at the Same Entity	54
	[F] Pharmacovigilance	54
§2.07	Trial Data	57
	[A] Introduction to Trial Data	57
	[B] Public Access to Trial Data	58
	[C] The Trial Master File: Essential Documents	58
	[D] Collection of Data	60
	[E] Protection of Data and Storage Requirements	62
	[F] Retention of Data	64
§2.08	Trial Amendments and Termination	64
	[A] Introduction to Trial Amendments and Terminations	64
	[B] Amendments by the Ethics Committee or the Competent Authority	64
	[C] Amendments by the Sponsor	65
	[1] Notice of Amendment	65
	[2] Deviations	66
	[D] Termination of the Trial	67
§2.09	First-in-Man Studies Following the TGN1412 Case ('TeGenero')	67
	[A] New CHMP Guidelines as a Result of the TeGenero Case	69
§2.10	Updated Clinical Trials Guidance from European Commission	70
§2.11	The Proposal for a Regulation of Clinical Trials on Medicinal Products for Human Use and Repealing Directive	71

Table of Contents

[A]	The New Regulation on Clinical Trials on Medicinal Products for Human Use	72
[1]	Scope	72
[B]	Proportionality: ‘Low-Intervention Clinical Trials’	72
[C]	New Procedures	73
[1]	The Authorisation Procedure	73
[2]	Summary of New Procedures	74
[3]	Application Dossier	75
[4]	The EU Portal and the European Medicines Agency Database for Safety Reporting	76
[5]	Sponsors	76
[6]	Ethics Committees	77
[7]	Damage Compensation and Fees	78
[8]	Inspections	78
[9]	Clinical Trials Coordination and Advisory Group	78
§2.12	Clinical Trials and Patent Legislation: The Bolar and Research Exceptions	79
§2.13	Guidelines/Publications	116
CHAPTER 3		
Obtaining a Marketing Authorisation		
<i>Sally Shorthose & Sarah Faircliffe</i>		119
§3.01	Approval of Medicines for Human Use: Securing a Marketing Authorisation	119
[A]	Introduction and Overview of the Processes	119
[B]	Goals of the Approval Process: Demonstration of Quality, Safety, and Efficacy	120
[C]	Legislative Background	120
[D]	Overview of the Application Dossier	122
[E]	Overview of the Marketing Authorisation Procedures	122
§3.02	Requirements of the Application Dossier	123
[A]	Required Contents of an Application Dossier	124
[1]	Manufacturing Authorisations	125
[a]	Assurance of Quality of All Constituents	126
[2]	New Active Substances	126
[3]	Orphan Drugs	127
[4]	Naming the Product	127
[5]	Required Product Information	128
[6]	Summary of Product Characteristics	128
[7]	Environmental Risks	129
[8]	Pharmacovigilance Systems	129
[9]	Submission of Test Results	129
[B]	Presentation of the Dossier—the Common Technical Document	130

Table of Contents

§3.03	The Centralised Procedure	131
	[A] Scope	131
	[1] Optional Scope	132
	[2] Mandatory Scope	132
	[B] Submission to the European Medicines Agency	133
	[C] Application and Approval Procedure	134
	[1] The Committee for Medicinal Products for Human Use	135
	[2] Rapporteur of the CHMP	136
	[3] CHMP Assessment	136
	[4] Commission Decision	137
	[5] Withdrawal	137
	[6] Publication	138
	[D] Marketing	138
	[E] Special Procedures	139
	[1] Compassionate Use	139
	[2] Conditional/Exceptional Circumstances Authorisations	139
	[F] Timing of the Process	140
	[G] Alternatives to the Centralised Procedure	142
§3.04	Mutual Recognition Procedure	142
	[A] Introduction	142
	[B] Application Process	143
	[C] Dispute Procedure	144
	[D] Timing of the Process	145
§3.05	Decentralised Procedure	145
	[A] Introduction	145
	[B] Application Process	146
	[C] Dispute Procedure	147
	[D] Timing of the Procedure	147
§3.06	The National Procedure	148
	[A] Introduction	148
	[B] Application Process	148
§3.07	Advantages and Disadvantages of the Four Procedures	149
	[A] The Centralised Procedure	149
	[B] The Mutual Recognition Procedure	149
	[C] The Decentralised Procedure	150
	[D] The National Procedure	150
§3.08	Continuing Validity, Renewal and Termination of Marketing Authorisations	152
§3.09	Guidelines/Publications	152
CHAPTER 4		
Conditional Marketing Authorisations		
	<i>Sally Shorthose</i>	155
§4.01	Introduction	155

Table of Contents

§4.02	Criteria for a CMA	156
	[A] New Marketing Authorisation Applications	156
	[B] Justification That the Medicinal Product Falls within the Scope of a CMA	156
	[1] Seriously Debilitating Diseases or Life-Threatening Diseases	157
	[2] Medicinal Products to Be Used in Emergency Situations	158
	[a] Influenza Pandemic	158
	[b] Bioterrorism	159
	[3] Orphan Medicinal Products	159
	[C] Requirements for a CMA	160
	[1] The Risk/Benefit Balance of the Product Is a Positive	160
	[2] It Is Likely That the Applicant Will Be Able to Provide Comprehensive Data?	160
	[3] Fulfilment of Unmet Medical Need	161
	[4] The Benefits to Public Health of Immediate Availability Outweigh the Risks Inherent in the Fact That Additional Data Are Still Required	162
	[D] Specific Obligations	162
	[E] Timeframe	163
	[F] Amendment to Full Marketing Authorisation	163
§4.03	Procedure	163
	[A] Prior to Submission of a CMA	163
	[B] Timing of the Submission and Documentation to Be Supplied	163
	[1] Documents to Be Submitted	164
	[a] General Requirements	164
	[b] Requirements for the Interim Report on the Specific Obligations	165
	[c] CHMP Assessment and Opinion	166
	[C] CHMP Assessment of a Request for a CMA	166
	[D] Information Included in the Summary of Product Characteristics and Package Leaflet	167
	[E] EMA Timetable	167
§4.04	Marketing Authorisation Granted in Exceptional Circumstances	168
§4.05	Guidelines/Publications	169
CHAPTER 5		
Supplementary Protection Certificates		
	<i>Tasmina Goraya</i>	171
§5.01	Introduction	171
§5.02	The Legislation	172
§5.03	Duration and Scope	174
	[A] Duration	174
	[1] Basic Term	174

Table of Contents

	[2] Paediatric Extensions for Medicinal Product SPCs	175
[B]	Scope	175
	[1] What Is a 'Product'?	176
	[2] The Distinction between a 'Product' and a 'Medicinal Product'	178
§5.04	The Procedure for Seeking SPC Protection	178
§5.05	Infringement and Invalidation	180
§5.06	Transitional Provisions	180
§5.07	Issues in Relation to Supplementary Protection Certificates	183
	[A] When Is a Product 'Protected by a Basic Patent in Force'	183
	[1] Construction of Patent Claims	183
	[2] Combination Products	184
	[3] Functional Specifications	185
	[4] Multiple SPCs Based upon a Single Patent	186
	[B] The Product Has Not Already Been the Subject of a Certificate	188
	[C] First Authorisation to Place the Product on the Market as a Medicinal Product	188
	[D] What Happens when the Basic Patent and Marketing Authorisation Have Different Holders?	190
	[E] What Form Can an SPC 'Claim' Take and What Effect Does It Have on the Scope of Protection Conferred?	191
CHAPTER 6		
Paediatrics		
	<i>Sally Shorthose & Sarah Faircliffe</i>	193
§6.01	Introduction	193
§6.02	European Regulatory Law Relating to Paediatric Medicinal Products	194
	[A] Overview of the EU Paediatric Regulation	194
	[B] The Paediatric Committee	195
	[C] Paediatric Investigation Plans	196
	[1] PIP Approval Procedures	198
	[2] PIP Compliance Check	199
	[3] Issues Concerning PIPs	199
	[D] PIP Exemptions, Waivers, and Deferrals	201
	[1] Exemptions	201
	[2] Waivers	202
	[3] Deferrals	202
§6.03	Rewards for PIP Completion	203
	[A] The Supplementary Protection Certificate Extension Reward	203
	[1] Zero and Negative Term SPCs	204
	[B] Rewards for Orphan Medicinal Products That Comply with Regulation (EC) No. 1901/2006	205
	[C] Free Scientific Advice from EMA	205
§6.04	Paediatric Use Marketing Authorisation	206

Table of Contents

§6.05	Post-approval Obligations	207
	[A] Duty to Place Product on Market	207
	[B] Pharmacovigilance	207
	[C] Product Discontinuation	208
	[D] The Paediatric Symbol	208
§6.06	Penalties	209
§6.07	Transparency	209
§6.08	Paediatric Research	210
§6.09	Future Developments	211
§6.10	Guidelines/ Publications	212
CHAPTER 7		
Advertising Medicinal Products for Human Use		
<i>Anne-Charlotte Le Bihan & Polina Lanckriet (Main Chapter, UK & France),</i>		
<i>Marc Martens & Nicolas Carbonnelle (Belgium), Ulf Grundmann (Germany),</i>		
<i>Hanneke Later-Nijland (Netherlands), Mauro Turrini (Italy), Ida Smed Sørensen</i>		
<i>& Mathilda Nordmark (Sweden) and Raquel Ballesteros & Lola</i>		
<i>Canalejo Rodriguez (Spain)</i>		
		213
§7.01	Introduction	213
§7.02	Legislative Basis	216
	[A] European Case Law on Advertising of Medicinal Products	216
	[B] The General Principles	218
	[C] Promotion of OTC Medicines	219
	[D] What Is Advertising?	221
	[E] Television Advertising	222
	[F] Proposals for Changes in the Legislation	223
§7.03	Self-Regulation in Europe	224
	[A] Advertising of Prescription-Only Products	224
	[1] The EFPIA Code	224
	[2] Scope of the EFPIA Code	225
	[3] EFPIA Code and Websites	225
	[B] Advertising of OTC Products	225
§7.04	Implementation in the United Kingdom	226
	[A] Legal Basis	226
	[B] Scope of the Regulations	227
	[C] Regulation by the MHRA	228
	[1] The Blue Guide	229
	[2] Advertising Using the Internet	229
	[3] Complaints to the MHRA	230
	[D] Sanctions	232
	[E] Self-Regulation	233
	[1] The ABPI and Prescription Medicines Code of Practice	233
	Authority	233
	[2] Proprietary Association of Great Britain (PAGB)	236

Table of Contents

	[a] The PAGB Consumer Code	236
	[b] The PAGB Professional Code	236
	[F] Advertising Standards Authority	237
	[G] Association of British Healthcare Industries (ABHI)	238
§7.05	Implementation in Germany	239
	[A] Legal Basis	239
	[B] Scope of the Advertising of Medicinal Products Act	239
	[C] National Sanctions	240
	[D] Role of the National Competent Authority	240
	[E] National Implementation Beyond Requirements of Directive 2001/83/EC	241
	[1] Testimonials	241
	[2] Internet Presentations	241
	[3] Further Requirements	242
§7.06	Implementation in the Netherlands	242
	[A] Legal Basis	242
	[1] The Medicines Act	242
	[2] Enforcement	243
	[3] Sanctions	243
	[4] Inspections	244
	[5] Cooperation with Other Regulating Institutes	245
	[B] Civil Law	245
	[C] Criminal Law	245
	[D] Self-Regulation	246
	[1] Enforcement	246
	[2] Sanctions	247
	[3] Advertising Code	247
	[a] information	248
	[b] Comparative Advertising	248
	[c] Samples	249
	[d] Internet Advertising	249
	[4] OTC Advertising Code	249
	[5] Guidance Documents	250
	[a] Gifts	250
	[b] Hospitality	250
	[c] Sponsoring and Grants	252
	[d] Services	252
	[E] Medical Devices	253
	[F] Healthcare Products	253
§7.07	Implementation in Italy	254
	[A] Legal Basis	254
	[B] Scope of the Decree	254
	[C] Role of the National Competent Authority	254
	[D] Self-Regulation for Promotion of Prescription-Only Products	255

Table of Contents

	[E] Self-Regulation for Promotion of OTC Products	255
	[F] General Advertising Rules	255
	[G] Regional Control	256
	[H] National Sanctions	256
	[I] Advertising on the Internet	256
§7.08	Implementation in Sweden	256
	[A] Legal Basis	256
	[B] Scope of the Regulations	258
	[C] Role of the MPA: The National Competent Authority	258
	[1] Complaints to the MPA	259
	[2] Sanctions	259
	[D] Self-Regulation	260
	[1] The LIF	260
	[2] The Ethical Rules	260
	[3] The IGM and the NBL	262
	[4] The IGM	262
	[5] The NBL	263
	[6] Agreements on Forms of Collaboration with the Healthcare Sector	264
	[7] Other Applicable Rules	264
§7.09	Implementation in Belgium	265
	[A] Legal Basis	265
	[B] Sanctions	265
	[C] Role of the National Competent Authority	266
	[D] Self-Regulation	266
	[E] Cases	267
	[F] General Advertising Rules	267
§7.10	Implementation in Spain	267
	[A] Regulatory Aspects	267
	[1] Legal Basis	267
	[2] The General Principles as Interpreted by Spanish Authorities	268
	[3] Advertising Aimed at Persons Qualified to Prescribe or Supply Medicinal Products	269
	[a] Advertising Using the Internet	269
	[4] Advertising Aimed at the General Public	270
	[B] Infringements and Remedies under the Law	271
	[C] Self-Regulation	273
	[1] Spanish Code of Good Practice for the Pharmaceutical Industry	274
	[2] Promotion of Medicines and Interaction with Healthcare Professionals	274
	[3] Relationships between the Pharmaceutical Industry and Patient Organisations	275

Table of Contents

	[D] Infringements and Remedies under the Codes	276
§7.11	Implementation in France	277
	[A] Legal Bases	277
	[1] Binding Rules	277
	[2] Non-binding Rules	279
	[B] Regulation by the ANSM	281
	[1] Drug Advertising Directed at Healthcare Professionals	281
	[2] Drug Advertising Directed at the Public	281
	[3] Medical Devices	281
	[C] Specific Forms of Advertising	282
	[1] Meetings and Congresses	282
	[2] Bonus and Gifts	282
	[3] Samples of Medicinal Products	282
	[D] Sanctions	283
	[1] Administrative Sanctions	283
	[a] Control of Advertising Directed at the Public	283
	[b] Control of Advertising Directed at Healthcare Professionals	283
	[2] Criminal Sanctions	284
§7.12	Future Developments	284
	[A] Introduction	284
	[B] Proposed Changes to Directive 2001/83/EC	285
	[C] Proposed Changes to Regulation 726/2004	286
Annex		286
CHAPTER 8		
Pharmacovigilance		
	<i>Sally Shorthose</i>	291
§8.01	Introduction	291
§8.02	Pre-authorisation, Pharmacovigilance	295
	[A] Legislative Framework	295
	[B] First-in-Man Trials	298
	[1] Case Study 1	298
	[C] Clinical Trials in Patients	299
	[D] The Investigator Brochure	299
	[E] Reporting SUSARs	299
§8.03	The Marketing Authorisation Application	300
	[A] Legislative Framework	301
	[B] The Requirements Set Out in Directive 2001/83/EC	303
	[C] The Reporting of Adverse Reactions	304
	[1] Reports to the Marketing Authorisation Holder	304
	[2] Reports from Patients/Consumers	306
	[3] Reports with Name of Active Substance Only	307
	[4] Literature Reports	307

Table of Contents

	[5] Reports from Non-medical Sources	308
	[6] Timescales for Expedited Reporting	308
	[7] MedDRA	309
	[8] Electronic Reporting	309
	[9] Pregnancy Registries	310
	[10] Lack of Efficacy	310
	[11] Abuse, Misuse, or Overdose	310
	[12] Public Health Emergency	311
§8.04	Periodic Safety Update Reports	311
	[A] Introduction	311
	[B] Contents of the PSUR	311
	[C] Periodicity of Submission of PSUR	312
	[D] PSUR Work-Sharing Initiative	313
§8.05	The Pharmacovigilance Activities of the Key Parties	314
	[A] The EMA	314
	[B] Pharmacovigilance Working Party	315
	[C] Competent Authorities of the Member States	316
§8.06	Risk Management and EU-RMP	319
	[A] Introduction	319
	[B] Content of the EU-RMP	320
	[C] Monitoring of the Risk/Benefit Balance and Identification of Safety Signals	321
	[D] Risk Management at the Marketing Authorisation Holder's Initiative	321
	[E] Risk Management at the EMA's Initiative	322
	[1] Case Study 2: Cerivastatin (Lipobay) Withdrawal	323
	[F] Risk Management at National Competent Authorities' Initiative	324
	[1] Case Study 3: Bupropion	324
§8.07	Compliance with Pharmacovigilance Obligations	325
	[A] Legal Basis for Pharmacovigilance Inspections	326
	[B] Composition of the Inspection Team	327
	[C] Timing of Inspections	327
	[D] Conduct of Pharmacovigilance Inspections	328
	[E] Common Findings of Inspections	330
	[F] Sanctions	332
§8.08	Summary of Recent Changes (PSMF)	333
	[A] Pharmacovigilance System Master File	334
	[1] (PSMF)	334
	[B] Co-ordination and Inspection: Pharmacovigilance Risk Assessment Committee (PRAC)	334
	[C] Specific Conditions Relating to PhV Affecting EMA	337
	[1] PSUR Requirements	337
	[2] Setup of Interconnected Web-Portals	337

	[3] GVP Guidelines	338
§8.09	Guidelines/Publications	339
CHAPTER 9		
Variations to Marketing Authorisations		
	<i>Tasmina Goraya</i>	341
§9.01	Reason for Variations	341
	[A] Changes Not Requiring a Variation	342
	[B] Variation Legislation	342
§9.02	Classification of Changes	342
	[A] Types IA and IB	342
	[1] Type IA	342
	[2] Type IB	343
	[3] Guidelines on Categories	343
	[4] Re-classification of Type IA and Type IB Variations	344
	[B] Type II	344
	[1] Definition	344
	[2] Type II Categories	345
	[3] The ICH Design Space Concept	345
	[a] Introduction	345
	[b] Process Analytical Technology	346
	[c] Quality Risk Management	346
	[C] Extensions	346
	[1] Changes in Pharmaceutical Form	347
	[2] Changes in Strength	347
	[D] Classification of Unforeseen Variations	347
§9.03	Substantive Requirements of the Variation Application	348
	[A] Variation Applications for Biological Medicinal Products	348
	[1] Issues Arising in Relation to Biologicals	348
	[2] Regulatory Guidelines	349
	[a] Quality Guidelines	349
	[b] Safety and Efficacy Requirements	350
§9.04	Variation Application Procedure	351
	[A] Forms and Format	351
	[B] Grouping of Applications	351
	[1] Grouping of Variations Granted under the Mutual Recognition, Decentralised and Centralised Procedures	351
	[2] Grouping of Variations to Purely National Marketing Authorisations	352
	[C] Work-Sharing Procedure	353
	[D] Products Authorised through Mutual Recognition	354
	[1] Type IA	354
	[2] Type IB	355
	[3] Type II	356

Table of Contents

[E]	Centrally Authorised Products	357
	[1] Advance Notice	357
	[2] Type IA and IB Variations	357
	[3] Type II Variations	357
[F]	Purely National Procedure	358
	[1] Type IA Variations	359
	[2] Type IB Variations	359
	[3] Type II Variations	359
[G]	Urgent Safety Restrictions	360
[H]	Human Influenza Vaccines	360
CHAPTER 10		
Combination Products		
	<i>Ina vom Feld</i>	361
§10.01	Introduction	361
§10.02	Requirements for Marketing Approval of Fixed-Combination Medicinal Products	362
	[A] The Application Dossier	362
	[B] The Application Procedure	362
	[C] Scientific References, Non-clinical Trials, and Clinical Trials	363
	[D] Necessity of Non-clinical and Clinical Trials	364
	[1] Situations where Additional Studies Are Necessary	365
	[2] Situations where Fewer Studies Are Necessary	366
	[a] Combinations Already Approved as Free Combination Therapy	366
	[b] Combination of the Components Already Approved as a Fixed-Combination Product	368
§10.03	Criteria for Approval of Fixed-Combination Medicinal Products	368
	[A] The Risk/Benefit Ratio	368
	[B] Relevance of Each Active Substance of the Combination	369
	[C] Relevance of the Specific Dosage Regime	369
	[D] Criteria for Combination Packs	369
§10.04	Regulatory Variations for Fixed-Combination Products in Eight Key EU Jurisdictions	370
§10.05	Guidelines/Publications	375
CHAPTER 11		
Abridged Procedure		
	<i>Hanneke Later-Nijland</i>	377
§11.01	Introduction	377
§11.02	Three Types of Abridged Procedures	378
	[A] Abridged Procedure Based on Cross-Reference to Data with Holder's Consent	379

[B]	Abridged Procedure Based on Bibliographic Application for Well Established Use	380
[1]	Well-established Medicinal Use	380
[2]	Ten Years of Use	381
§11.03	Abridged Procedure for Generic Products	381
[A]	Data Protection of a Registration File for 6 or 10 Years	382
[B]	Data Protection and Marketing Exclusivity, 8 + 2 Years	384
[C]	Data Protection Rules Applicable within the EU until 30 October 2015	385
[D]	European Reference Medicinal Product	386
[1]	Global Marketing Authorisation	387
[2]	Reference to Products Authorised in the Member States Cyprus, Lithuania, Malta, Poland and Slovenia	388
[3]	Similar Biological Medicinal Products	388
[E]	Essential Similarity and Generic Medicinal Product	389
[1]	Development of 'Essentially Similar' and Scope of Abridged Procedure for Generic Medicinal Products up to October/November 2005	389
[a]	Meaning of 'Essential Similarity'	390
[b]	Scope of Application of the Hybrid Abridged Procedure	391
[c]	Essential Similarity and Line Extensions	393
[d]	Differences in Active Substance	393
[F]	Abridged Procedures for Generic Medicinal Products after October 2005	395
[1]	Definition of 'Generic Product' (Instead of 'Essentially Similar')	395
[a]	Same Qualitative and Quantitative Composition	395
[b]	Same Pharmaceutical Form	396
[c]	Bioequivalence Demonstrated by Studies	396
[d]	Salts, Esters, Ethers, Isomers, Mixtures, Complexes or Derivations	396
[e]	The Hybrid Procedure	397
[f]	New Active Substance	397
[G]	Additional Terms for Protection of Line Extensions	399
[1]	Extension for New Therapeutic Indication	399
[2]	Extension for New Indications for Well-established Substances	401
[3]	Change of Supply Status	402
CHAPTER 12		
Orphan Drugs		
<i>Sarah Faircliffe</i>		
§12.01	Introduction	405

Table of Contents

§12.02	The EU Orphan Drug Laws	406
§12.03	Applications for Orphan Designation	406
	[A] Pre-application Notice and Meeting	406
	[B] Application Contents and Format	407
	[C] Application Review: The Committee for Orphan Medicinal Products (COMP)	408
	[D] Criteria for Orphan Designation	409
	[1] Medicinal Product	409
	[2] Article 3(1) Requirements	409
	[3] Article 3(1)(a) Requirements	410
	[a] The Prevalence Criterion	410
	[b] The Insufficient Return on Investment Criterion	412
	[c] Medical Plausibility	414
	[4] Article 3(1)(b) Requirements	414
	[a] Existing Satisfactory Method	415
	[b] Significant Benefit Assumption	416
	[E] Clinical Data at the Designation Stage	417
	[F] Timing of Designation Applications	418
	[G] Application Approval and Appeal Process	418
	[H] Annual Review	419
	[I] Amendment of a Designation	419
§12.04	Orphan Medicinal Product Marketing Authorisation	419
	[A] The Centralised Procedure	420
	[B] Confirmation of Orphan Designation Criteria	420
§12.05	Market Exclusivity and Other Incentives	420
	[A] Protocol Assistance and Fee Reductions	421
	[B] Market Exclusivity	422
	[1] Meaning of 'Similar Medicinal Product'	422
	[2] 'Breaking' Market Exclusivity	423
	[3] Procedure for Assessing Similarity and Derogations	424
	[4] Impact of a Second Orphan Authorisation Granted under the Derogation Provisions	425
	[C] Market Exclusivity Review: Possible Reduction In Term	425
§12.06	Transfer of Orphan Designation	426
§12.07	Transparency	427
§12.08	Research	427
§12.09	Future Developments	428
§12.10	Guidelines/Publications	430
CHAPTER 13		
Biologicals		
	<i>Elizabeth Fuller</i>	433
§13.01	Introduction	433

Table of Contents

§13.02	Quality Testing for Biologicals	435
	[A] Non-clinical Aspects	435
	[1] Biological Activity and Toxicological Data	435
	[2] Selection of Animal Models	436
	[3] Number and Gender of Animals	436
	[4] Administration/Dose Selection	436
	[5] Immunogenicity	436
	[B] Clinical Trials	437
	[C] The Biologics Working Party	438
§13.03	Marketing Authorisations for Biologicals	439
	[A] Choice of Marketing Authorisation Procedure	439
	[B] Marketing Authorisation Applications for Biologicals: General Requirements	440
	[1] General Information	440
	[2] Information Relating to the Starting and Raw Materials	441
	[3] Manufacturing Process of the Active Substance(s)	441
	[4] Description and Composition of the Finished Medicinal Product	442
	[C] Marketing Authorisation Applications for Biologicals: Specific Product Requirements	442
	[1] Plasma-Derived Medicinal Products	442
	[2] Vaccines	443
	[3] Advance Therapy Medicinal Products	443
	[a] Gene Therapy Medicinal Products	443
	[b] Somatic Cell Therapy Medicinal Products	444
§13.04	Post-marketing Authorisation Approval Requirements	447
	[A] Changes to the Manufacturing Process	447
§13.05	Biosimilars	448
	[A] Marketing Authorisation Application Routes for Biosimilars	448
	[1] The Application of the Abridged Application to Biosimilars	449
	[2] Similar Biological Application	450
	[3] Market and Data Exclusivity	451
	[B] Marketing Authorisation Applications for Biosimilars: General Requirements	452
	[1] Biosimilars Guidelines	453
	[2] 'Me-Betters'	454
	[C] Pharmacovigilance	455
	[1] International Non-proprietary Names	455
§13.06	Further Developments	456
	[A] Guidelines/Publications	457

Table of Contents

CHAPTER 14	
Homeopathic, Herbal, and Traditional Herbal Medicinal Products	
<i>Colette Mulder</i>	459
§14.01 Introduction to Homeopathic, Herbal, and Traditional Herbal Medicinal Products	459
§14.02 Homeopathic Medicinal Products	461
[A] Introduction to Homeopathic Medicinal Products	461
[B] Legal History of Homeopathic Medicinal Products	462
[C] Current Legislative Framework for Homeopathic Medicinal Products	463
[D] Definition of Homeopathic Medicinal Product	463
[E] Homeopathic Simplified Registration Procedure	464
[F] Application Procedure for Homeopathic Simplified Registration	465
[G] Article 16 Authorisation Procedure	466
[H] Applicability of Other Provisions of the Directive for Homeopathic Medicinal Products	467
§14.03 Herbal and Traditional Herbal Medicinal Products	468
[A] Introduction to Herbal and Traditional Herbal Medicinal Products	468
[B] Herbal Medicinal Products	469
[1] Definition of Herbal Medicinal Products	469
[2] General Marketing Authorisation Procedure for Herbal Medicinal Products	469
[C] Traditional Herbal Medicinal Products	470
[1] Current Legislative Framework for Traditional Herbal Medicinal Products	470
[2] Definition of Traditional Herbal Medicinal Products	470
[3] Traditional Use Registration	470
[4] Application Procedure for Traditional Use Registration	472
[5] Labelling, Package Leaflet, and Advertising of Traditional Herbal Medicinal Products	474
[6] Other Applicable Provisions for Traditional Use Registration	474
[D] Safety and Efficacy of Herbal and Traditional Herbal Medicinal Products	475
[E] Manufacturing and Quality of Herbal and Traditional Herbal Medicinal Products	475
[F] Committee on Herbal Medicinal Products (HMPC)	476
[G] Community Herbal Monograph	477
[H] Community List	478

CHAPTER 15	
Advanced Therapy Medicinal Products	
<i>Marc Martens & Nicolas Carbonnelle</i>	479
§15.01 Introduction	479
[A] History	479
[B] Definitions	481
[1] Gene Therapy Medicinal Products (Section 2.1, Part IV, Annex I to Directive 2001/83/EC)	481
[2] Somatic Cell Therapy Medicinal Products (Section 2.2, Part IV, Annex I to Directive 2001/83/EC)	481
[3] Tissue-Engineered Products (Article 2 (b) of the ATMP Regulation)	482
[C] Combined ATMPs and the Classification Rules	483
[1] Combined ATMPs	483
[2] Classification Rules	484
§15.02 Relationship between the ATMP Regulation and Other European Legislation	485
§15.03 The Market Access for ATMPs	486
[A] Ordinary Regime	486
[1] The Procedure	486
[2] The Committee for Advanced Therapies	486
[a] Role and Responsibilities	487
[b] Composition	487
[B] Exemptions	488
§15.04 The Marketing Authorisation Application Dossier	489
[A] Specific Requirements Set Out in Part IV of Annex I to Directive 2001/83/EC	489
[B] Other Requirements Applicable to ATMPs	491
[1] Summary of Product Characteristics, Labelling and Package Leaflet	491
[2] Post-authorisation Requirements	491
[a] Follow-Up of Efficacy and Risk Management	491
[b] Traceability	492
§15.05 Incentives for Small and Medium Sized Enterprises	492
§15.06 Transitional Period	493
§15.07 Perspectives	493
§15.08 Conclusion	494
CHAPTER 16	
Medical Devices	
<i>Ulf Grundmann & Elisabeth Kohoutek</i>	497
§16.01 Introduction	497
§16.02 Medical Devices	498
[A] European Legal Provisions	498

Table of Contents

[B]	Definition of Medical Device	499
[C]	Borderline Products	500
	[1] Legislative Guidance	501
	[2] Judicial Guidance	501
[D]	Classification of Medical Devices	503
[E]	Essential Requirements for Marketing of Medical Devices	505
[F]	Conformity Assessment Procedures	506
[G]	Marketing Authority: Notified Bodies	507
[H]	CE Marking	509
	[1] CE Labelling	510
	[2] Value of the CE Marking	510
	[3] Misconceptions Regarding CE Marking	511
[I]	Registration of Persons Placing Medical Devices on the Market	512
[J]	Vigilance Procedure	512
[K]	Surveillance Role of Member States and Competent Authorities	514
[L]	Institutes, Organisations, and Associations	515
§16.03	In Vitro Diagnostic Medical Devices	515
	[A] Essential Requirements for Marketing in Vitro Diagnostic Medical Devices	516
	[B] Requirements for Marketing in Vitro Medical Devices for Self-Testing	517
	[C] Conformity Assessment Procedures	518
	[1] Obligations of the Manufacturer	519
	[2] Obligations of Parallel Traders	519
	[D] Vigilance Procedure	520
§16.04	Active Implantable Medical Devices	521
	[A] Essential Marketing Requirements for Active Implantable Medical Devices	522
	[B] Vigilance Procedure	522
§16.05	How to Advertise Medical Devices	523
	[A] German Provisions Regarding the Advertising of Medical Devices	524
	[1] Misleading Claims	525
	[2] Citations of Scientific Studies and Expert Opinions	525
	[3] Give-aways	525
	[4] Testimonials	526
	[B] Unfair Competition Law Provisions and Codes of Conduct	527
§16.06	Future Developments	527
§16.07	Guidelines/Publications	541

CHAPTER 17	
Parallel Trade	
<i>Ina vom Feld</i>	543
§17.01 Introduction to Parallel Trade	543
§17.02 Parallel Distribution Law	544
[A] EMA Notice	544
[B] Necessary Licenses for Parallel Distributors	545
[C] Other Requirements	546
[1] Changes in the Package or Label	546
[2] Notice to Local Authorities	547
[3] Marketing Authorisation Updates	547
[4] Maintenance Notice	547
[5] Quality Control	548
[6] Falsified Medicines	548
§17.03 Parallel Importation	549
[A] Parallel Importation Law	549
[B] The Simplified Procedure	550
[C] General Requirements for the Simplified Procedure	552
§17.04 Intellectual Property Law	553
[A] Introduction	553
[B] Patent Rights and Parallel Trade	553
[1] Exhaustion of Patent Rights	554
[2] Specific Mechanism	555
[C] Trademark Law and Parallel Trade	558
[1] The Repackaging Does Not Affect the Product	559
[2] The Repackaging Is Not Likely to Damage Reputation	559
[3] Indication of the Original Manufacturer and the Repackager	560
[4] Notice to the Trademark Owner	560
[5] The Repackaging Is 'Necessary'	560
[6] Burden of Proof	561
[7] Rebranding	562
§17.05 Competition Law	562
§17.06 Regulatory Variations for Parallel Imports in Eight Key EU Jurisdictions	562
§17.07 Guidelines/Publications	576
CHAPTER 18	
Competition Law in the Pharmaceutical Sector	
<i>José Rivas, Geoffroy van de Walle de Ghelcke & Carmen Feito Pérez</i>	579
Introduction	579
§18.01 Market Definition in the Pharmaceutical Sector	579
[A] Approved Medicines	580
[B] Active Substances	581

Table of Contents

	[C] Pipeline Products	581
§18.02	Article 101 of the TFEU	582
	[A] The Application of Article 101(1) TFEU	582
	[1] The Definition of an Undertaking	582
	[2] Definition of Agreements, Concerted Practices, and Decisions of Associations	583
	[a] Agreements	583
	[b] Concerted Practices	584
	[c] Decisions by Association of Undertakings	584
	[3] A Restriction of Competition by Object or Effect	585
	[4] An Appreciable Restriction of Competition: <i>De Minimis</i>	585
	[5] An Appreciable Effect on Trade between Member States	586
	[B] The Application of Article 101(3) TFEU	586
	[1] Individual Exceptions	587
	[2] Block Exemptions	587
	[a] The Block Exemption Regulation on Technology Transfer (TTBER)	587
	[b] The Block Exemption Regulation on Research and Development	589
	[C] Selection of Cases	590
	[1] Agreements between Originators and Generics	590
	[D] Reverse Payment Patent Settlements	590
	[E] Other Agreements having the Effect of Delaying Generic Market Entry	591
	[1] Other Anticompetitive Agreements	592
§18.03	Article 102 of the TFEU	592
	[A] Establishing Dominance under Article 102	592
	[B] Abuse of a Dominant Position	594
	[1] Non-price-Based Exclusionary Conduct	595
	[a] Misuse of IP Rights	595
	[b] Refusal to Supply	596
	[c] Other Non-price-Based Exclusionary Abuses	596
	[2] Price-based Exclusionary Conduct	597
	[a] Fidelity Rebates and Exclusive Purchase Obligations	597
§18.04	Parallel Trade	597
§18.05	The EU Merger Control Regulation	598
	[A] Merger Control Procedure	599
	[B] Substantive Assessment	600
	[1] Horizontal Mergers	600
	[2] Non-horizontal Mergers	601
	[C] Selection of Cases	601
	[1] GlaxoWellcome/Smithkline Beecham	601
	[2] Novartis/Hexal	602

Table of Contents

§18.06	State Aid	602
	[A] Definition of State Aid under the Treaty	603
	[B] Exemptions	603
§18.07	Guidelines/Publications	606
	Appendix Guidelines and Publications	609
	Table of Cases	621
	Directives	629
	Other Legislation	633
	Regulations	635
	Index	639

<http://www.pbookshop.com>